NEW YORK (360Dx) – Mologic is expanding into the US market and targeting the near-term commercialization of rapid respiratory diagnostics for use in the home.
Simultaneously, the Bedford, UK-based company is developing rapid sepsis diagnostics for use in primary care and emergency room settings.
The firm is taking its in-home monitoring systems for chronic obstructive pulmonary disease (COPD) and cystic fibrosis and professional-use sepsis confirmation system through clinical trials, and it anticipates launching them in the next couple of years in the US and Europe.